Clinical trial for Anxiety Disorders
Official title Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety: R33 Phase
ClinicalTrials.gov ID: NCT07818876
What this study is testing
- What it's testing
- The study wants to see if a personalized cognitive bias modification can reduce anxious thinking and lower anxiety symptoms in young people.
- Who it's for
- It is looking for teens aged 10 to 17 who have a primary anxiety disorder such as generalized, separation, or social anxiety.
- What's involved
- Participants will either do 16 computer sessions that target threat thinking or attend four one‑hour sessions of cognitive restructuring, both lasting about four weeks.
- Time commitment
- The program lasts four weeks, with either 16 short computer tasks or four one‑hour therapy sessions, and involves regular check‑ins to track progress.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 10 to 17
You may be able to join if
- Provision of signed and dated informed consent form by parent/legal guardian and signed youth assent.
- Youth and parent/legal guardian speak sufficient English to engage in study procedures.
- Youth is aged 10 to 17 inclusive, at time of signing consent/assent and completion of Visit 1 procedures.
- Youth meets full diagnostic criteria for primary Generalized Anxiety Disorder, Separation Anxiety Disorder, or Social Anxiety Disorder as assessed by...
- Youth otherwise meeting study entry criteria, who are receiving treatment for a stable medical or psychiatric condition, may be included providing...
You likely can't join if
- Requires treatment other than CBM-I/CR: namely, youths with severe anxiety indicating need for higher level of care (e.g., psychiatric...
- At Visit 1, is currently in alternate psychosocial intervention for any reason or has plans to initiate any psychosocial intervention for any reason.
- Has previously received any type of cognitive bias modification (attention or interpretation bias as target) at the BRAVE Lab or elsewhere.
- The family indicates they are no longer interested or able to participate in the study after Visit 1 (in which it is determined that the family is...
- Has significant uncorrected vision impairment (e.g., uncorrected blindness) that precludes participation in the computerized assessment and...
See the full eligibility criteria
- Provision of signed and dated informed consent form by parent/legal guardian and signed youth assent.
- Youth and parent/legal guardian speak sufficient English to engage in study procedures.
- Youth is aged 10 to 17 inclusive, at time of signing consent/assent and completion of Visit 1 procedures.
- Youth meets full diagnostic criteria for primary Generalized Anxiety Disorder, Separation Anxiety Disorder, or Social Anxiety Disorder as assessed by the Anxiety Disorders Interview Schedule-IV (ADIS-IV) during Visit 1.
- Youth otherwise meeting study entry criteria, who are receiving treatment for a stable medical or psychiatric condition, may be included providing that medication and dose have been stable for at least six weeks (e.g...
- Youth must have a standard score of at least 85 on the Wechsler Abbreviated Scale of Intelligence, Vocabulary and Matrix Reasoning subtests, as well as the Wide Range Achievement Test-4 Reading subtest (administered...
- Youth must have access to a desktop or laptop computer and access to internet at home or can access one at their school or local library for the at-home portion of the computer training program.
- Requires treatment other than CBM-I/CR: namely, youths with severe anxiety indicating need for higher level of care (e.g., psychiatric hospitalization), or primary major depressive disorder, bipolar disorder, psychosis...
- At Visit 1, is currently in alternate psychosocial intervention for any reason or has plans to initiate any psychosocial intervention for any reason.
- Has previously received any type of cognitive bias modification (attention or interpretation bias as target) at the BRAVE Lab or elsewhere.
- The family indicates they are no longer interested or able to participate in the study after Visit 1 (in which it is determined that the family is eligible) but before the family is assigned by chance or told of their...
- Has significant uncorrected vision impairment (e.g., uncorrected blindness) that precludes participation in the computerized assessment and intervention components of the study.
The study team makes the final eligibility decision.
Where it is enrolling
- Denver, Colorado, United States
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 10 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Denver, Colorado, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.